Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06213233 · ClinicalTrials.gov registry record · Phase 2

MIVetsCan: Cannabidiol (CBD)-Care Trial

A Phase 2 study of Pain, Chronic, sponsored by Kevin Boehnke.

Recruiting
Registry status
Phase 2
Development phase
468
Enrollment target
1
Study location

NCT06213233 is a Phase 2 study of Pain, Chronic that is actively recruiting participants, run by Kevin Boehnke. The registered enrollment target is 468 participants, below the 712-participant average among 48 other Pain, Chronic trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06213233, a Phase 2 study of Pain, Chronic, is actively recruiting participants, sponsored by Kevin Boehnke.

RECRUITING
Registry status
Phase 2
Development phase
468 participants
Enrollment target
1
Study location

Study Summary

This research is studying the effects of cannabidiol (CBD), an active component from cannabis (a.k.a. marijuana), on Veterans' chronic pain. The purpose of this study is to better understand if CBD can improve pain symptoms in Veterans with chronic pain. Eligible participants will be randomly assigned to receive either placebo medication (not active) or CBD during the study period. The study hypotheses: \- CBD would improve overall pain symptoms compared to placebo

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Cannabidiol

Study Locations (1)

Michigan

  • University of Michigan - Ann Arbor

Trial Details

FieldValue
Enrollment Target 468 participants
Start Date 2024-02-12
Est. Completion 2026-12
Phase Phase 2

Sponsor

Kevin Boehnke

2 total trials

What the Registry Record Tells You About NCT06213233

The ClinicalTrials.gov registry entry for NCT06213233 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 468 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 712-participant average among 48 other Pain, Chronic trials with a reported enrollment target (34% lower). The listed sponsor is Kevin Boehnke, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pain, Chronic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06213233 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT06213233 about?

NCT06213233 is a clinical study titled "MIVetsCan: Cannabidiol (CBD)-Care Trial". This research is studying the effects of cannabidiol (CBD), an active component from cannabis (a.k.a. marijuana), on Veterans' chronic pain. The purpose of this study is to better understand if CBD can improve pain symptoms in Veterans with chronic pain. Eligible participants will be randomly assig...

What is the current status of trial NCT06213233?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 468 participants. The study started on 2024-02-12. Estimated completion is 2026-12.

What conditions does trial NCT06213233 study?

This clinical trial studies the following conditions: Pain, Chronic.

What interventions are being tested in trial NCT06213233?

The interventions under investigation include: Placebo (DRUG), Cannabidiol (DRUG).

Who is sponsoring clinical trial NCT06213233?

This trial is sponsored by Kevin Boehnke, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06213233 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain, Chronic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.